• Please log in or register to access this feature.

Viral Hepatitis

You have full text access to this OnlineOpen article

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen–positive chronic hepatitis B†‡§

  1. Ting-Tsung Chang1,¶,*,
  2. Ching-Lung Lai2,
  3. Seung Kew Yoon3,
  4. Samuel S. Lee4,
  5. Henrique Sergio M. Coelho5,
  6. Flair Jose Carrilho6,
  7. Fred Poordad7,
  8. Waldemar Halota8,
  9. Yves Horsmans9,
  10. Naoky Tsai10,
  11. Hui Zhang11,
  12. Daniel J. Tenney11,
  13. Ricardo Tamez12,
  14. Uchenna Iloeje11

Article first published online: 4 JAN 2010

DOI: 10.1002/hep.23327

Issue

Hepatology

Hepatology

Volume 51, Issue 2, pages 422–430, February 2010

Additional Information

How to Cite

Chang, T.-T., Lai, C.-L., Kew Yoon, S., Lee, S. S., Coelho, H. S. M., Carrilho, F. J., Poordad, F., Halota, W., Horsmans, Y., Tsai, N., Zhang, H., Tenney, D. J., Tamez, R. and Iloeje, U. (2010), Entecavir treatment for up to 5 years in patients with hepatitis B e antigen–positive chronic hepatitis B. Hepatology, 51: 422–430. doi: 10.1002/hep.23327

Author Information

  1. 1

    Medical College, National Cheng Kung University, Tainan, Taiwan, ROC

  2. 2

    Queen Mary Hospital, Hong Kong, China

  3. 3

    Kangnam St. Mary Hospital, The Catholic University of Korea, Seoul, Korea

  4. 4

    Foothills Provincial General Hospital, University of Calgary, Calgary, Canada

  5. 5

    Hospital Universitario Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

  6. 6

    Department of Gastroenterology, University of São Paulo School of Medicine, São Paulo, SP, Brazil

  7. 7

    Department of Hepatology and Liver Transplantation, Cedars-Sinai Medical Center, Los Angeles, CA

  8. 8

    Department of Infectious Diseases and Hepatology, Nicolaus Copernicus University, Bydgoszcz, Poland

  9. 9

    Department of Hepatology and Gastroenterology, Cliniques St Luc, Brussels, Belgium

  10. 10

    University of Hawaii, Honolulu, HI

  11. 11

    Bristol-Myers Squibb Co. (BMS), Research and Development, Wallingford, CT

  12. 12

    Bristol-Myers Squibb Co., Research and Development, Princeton, NJ

  1. fax: +886-6-209-5233

*138 Sheng-Li Road, Tainan, 70428, Taiwan, Republic of China

  1. †

    Potential conflicts of interest: Ting-Tsung Chang: Research support from Bristol-Myers Squibb; Ching-Lung Lai: Research support and consultancy fees from Bristol-Myers Squibb. SeungKew Yoon: Nothing to disclose. Samuel S. Lee: Consultancy fees from Roche, Gilead, Bristol-Myers Squibb, and Novartis. Speakers' bureau for Roche, Gilead, and Bristol-Myers Squibb. Henrique Sergio M Coelho: Nothing to disclose. Flair Jose Carrilho: Research support from Bristol-Myers Squibb. Fred Poordad: Research support, speakers' bureau fees, and consultancy fees from Bristol-Myers Squibb. Waldemar Halota: Nothing to disclose. Yves Horsmans: Consultancy fees from Bristol-Myers Squibb. Naoky Tsai: Research support, speakers' bureau fees, and consultancy fees from Bristol-Myers Squibb. Hui Zhang: BMS employee. Daniel J. Tenney: BMS employee. Ricardo Tamez: BMS employee. Uchenna Iloeje: BMS employee.

  2. ‡

    In addition to the authors, the following investigators participated in the study: Asia/Pacific: Nurul Akbar, Marilyn Arguillas, You-Chen Chao, Su-Kiun Chin, Kwang-Hyub Han, Simon Huang, Ian Kronborg, Alice Lee, Jacob George, Sik-To Lai, Shou-Dong Lee, Yun-Fan Liaw, Chee Chian Lim, Gin-Ho Lo, Yiu Wing Luk, George Marinos, Ismail Merican, Rosmawati Mohamed, Eng Keat Ooi, Stuart Roberts, William Sievert, Jose Sollano, Chee Kiat Tan, Judy Lao-Tan, Tawesak Tanwandee, Shun-Sheng Wu, Felix Zano. Europe and Middle East: Edward Antuch, Yucel Batur, Anna Boron-Kaczmarska, Pavel Chalupa, Isabelle Colle, Andrzej Gladysz, Barbara Gocman, Zbigniew Gonciarz, Markus H. Heim, Vasily Isakov, Ran Tur-Kaspa, Sabahattin Kaymakoglu, Wieslaw Kryczka, Jan Kuydowicz, Yoav Lurie, Tomasz Mach, Francesco Mazzotta, Roma Modrzewska, Beat Muellhaupt, Assy Nimer, Court Pedersen, Vladimir Rafalsky, Maria Raptopoulou-Gigi, Daniel Shouval, Marian Sikora, Cihan Yurdaydin, Konstantin Zhdanov. USA and Canada: Frank H. Anderson, Thomas Boyer, Robert Brown, Robert G. Gish, Anna Lok, Gerald Minuk, Raymond Rubin, Eugene Schiff, Morris Sherman. Latin America: Antonio A. Barone, Fernando Bessone, Hugo Cheinquer, Laura E. Cisneros Garza, Luiz Guilherme Costa Lyra, Hugo Fainboim, Jorge Ferrandiz, Maria Lucia Ferraz, Fernando L. Goncales, Jr, Mario Pessoa, Marcelo Silva, Ruben Terg.

  3. §

    The sponsor designed the study in collaboration with expert hepatologists. The sponsor also collected the data, monitored study conduct, performed the statistical analyses, and coordinated writing of the article with all authors.

  4. fax: +886-6-209-5233

Publication History

  1. Issue published online: 25 JAN 2010
  2. Article first published online: 4 JAN 2010
  3. Manuscript Accepted: 11 SEP 2009
  4. Manuscript Received: 4 MAR 2009

Funded by

  • Bristol-Myers Squibb

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (371K)

References

  • 1
    Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003; 362: 2089–2094.
  • 2
    Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepatol 2004; 11: 97–107.
    Direct Link:
  • 3
    Chen C-J, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65–73.
  • 4
    Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen C-J. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678–686.
  • 5
    Keeffe EB, Dieterich DT, Han SHB, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008; 6: 1315–1341.
  • 6
    Lok AS, McMahon BJ. Chronic hepatitis B. HEPATOLOGY 2007; 45: 507–539.
    Direct Link:
  • 7
    Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263–283.
  • 8
    Cooksley WGE, Piratvisuth T, Lee SD, Mahachai V, Chao YC, Tanwandee T, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepatol 2003; 10: 298–305.
    Direct Link:
  • 9
    Lau GKK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682–2695.
  • 10
    Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334: 1422–1427.
  • 11
    Chang T-T, Lai CL, Chien RN, Guan R, Lim SG, Lee CM, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis. J Gastroenterol Hepatol 2004; 19: 276–1282.
    Direct Link:
  • 12
    Lai CL, Gane E, Hsu CW, Thongsawat S, Wang Y, Chen Y, et al. Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine vs. lamivudine [Abstract]. HEPATOLOGY 2006; 44 ( Suppl. 1): 222A.
  • 13
    Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 2576–2588.
  • 14
    Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442–2455.
  • 15
    Marcellin P, Chang T-T, Lim SGL, Sievert W, Tong M, Arterburn S, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. HEPATOLOGY 2008; 48: 750–758.
    Direct Link:
  • 16
    Heathcote EJ, Gane EJ, deMan RA, Chan S, Sievert W, Mauss S, et al. Two-year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-positive patients with chronic hepatitis B (Study 103), preliminary analysis [Abstract]. HEPATOLOGY 2008; 48 ( Suppl.): 376A.
  • 17
    Snow-Lampart A, Chappell BJ, Curtis M, Zhu Y, Borroto-Esoda K. Week 96 resistance surveillance for HBeAg positive and negative subjects with chronic HBV infection randomized to receive tenofovir DF 300mg QD [Abstract]. HEPATOLOGY 2008; 48 ( Suppl.): 745A.
  • 18
    Chang TT, Gish RG, de Man RA, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001–1010.
  • 19
    Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133: 1437–1444.
  • 20
    Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. HEPATOLOGY 2006; 44: 1656–1665.
    Direct Link:
  • 21
    Tenney DJ, Rose RE, Baldick CJ, Levine SM, Pokornowski KA, Walsh AW, et al. Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007; 51: 902–911.
  • 22
    Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside naive patients is rare through 5 years of therapy. HEPATOLOGY 2009; 49: 1503–1514.
    Direct Link:
  • 23
    Colonno RJ, Rose R, Pokornowski K, Baldick, CT, Eggers, B, Yu D, et al. Four-year assessment of entecavir resistance in nucleoside naïve and lamivudine refractory patients [Abstract]. J Hepatol 2007; 46 ( Suppl. 1): S294.
  • 24
    Yuen MF, Yuan HJ, Wong DK, Yuen JC, Wong WM, Chan AO, et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 2005; 54: 1610–1614.
  • 25
    Iloeje U, Yang H-I, Su J, Chen C-F, Jen C-L, You S-L, et al. HBV viral load less than 104 copies/mL is associated with significant risk of hepatocellular carcinoma in chronic hepatitis B (CHB) patients: an update from the R. E.V.E.A.L.-HBV study [Abstract]. HEPATOLOGY 2007; 46 ( Suppl. 1): 640A.
  • 26
    Takehara T, Hayashi N, Takaguchi K, Yokosuka O, Fujioka S, Shindo M, et al. Efficacy and safety of 3 years treatment with entecavir (ETV) in Japanese nucleoside-naïve patients with chronic hepatitis B (CHB) [Abstract]. Hepatol Int 2008; 2: S311.
View Full Article (HTML) Get PDF (371K)